The new division — called Celmatix Biosciences — will focus on women's health indications with high unmet need including reproductive disorders and menopause.
The Fertilome test, a multigene sequencing panel, assesses a number of markers that have been associated with conditions that affect fertility.
The partners plan to investigate whether a woman’s response to ovarian stimulation during IVF treatment is linked to genomic characteristics.
The firm recently won $4.5 million as well as approval for its Fertilome test from New York state, though some have questioned the test's clinical utility.
The award is one of 121 for projects in New York City this year, totaling $64.8 million.
The firm has secured NYS approval for its sequencing-based 32-gene Fertilome assay, which it originally launched in January.
The companies will recruit and track a cohort of women to study environmental, genetic, and lifestyle factors that may contribute to fertility outcomes.
Celmatix's Fertilome test aims to give women genetic insight into their fertility.
The company's new blood-based test is the first clinical test offering that the company will be offering at its New York-based CLIA laboratory.
They will work to accelerate the launch of Celmatix's infertility genetics tests and develop early screening tests for declining ovarian function.
An artificial intelligence-based analysis suggests a third group of ancient hominins likely interbred with human ancestors, according to Popular Mechanics.
The New York Times Magazine looks into paleogenomics and how it is revising what's know about human history, but also possibly ignoring lessons learned by archaeologists.
The Economist reports on Synthorx's efforts to use expanded DNA bases they generated to develop a new cancer drug.
In Science this week: reduction in bee phylogenetic diversity, and more.